{"id":682203,"date":"2023-12-21T15:10:01","date_gmt":"2023-12-21T15:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=682203"},"modified":"2023-12-21T15:10:01","modified_gmt":"2023-12-21T15:10:01","slug":"extensive-stage-small-cell-lung-cancer-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/extensive-stage-small-cell-lung-cancer-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated_682203.html","title":{"rendered":"Extensive Stage Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1703154730.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Extensive Stage Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)\" src=\"https:\/\/www.abnewswire.com\/uploads\/1703154730.png\" alt=\"Extensive Stage Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Extensive Stage Small Cell Lung Cancer Pipeline Insight 2023<\/strong>&rdquo; report provides comprehensive insights about 40+ Extensive Stage Small Cell Lung Cancer companies and 40+ pipeline drugs in the Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the Extensive Stage Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Extensive Stage Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Extensive Stage Small Cell Lung Cancer pipeline report depicts a robust space with 40+ Extensive Stage Small Cell Lung Cancer companies working to develop 40+ pipeline therapies for Extensive Stage Small Cell Lung Cancer treatment.<\/li>\n<li>The leading Extensive Stage Small Cell Lung Cancer Companies working in the market includes <em>Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., aizhou HoudeAoke Biomedical Co., Ltd., Celgene, MedImmune, Xcovery Holding Company LLC, Lee&#8217;s Pharmaceutical Limited, Merck &amp; Co, Astex Pharmaceuticals<\/em>, and others.<\/li>\n<li>Promising Extensive Stages Small Cell Lung Cancer Pipeline Therapies in the various stages of development includes Ifinata<em>mab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin\/etoposide, <\/em>and others.<\/li>\n<li><strong><em>December 2023: Hoffmann-La Roche<\/em><\/strong> announced a study of Phase 3 clinical trials for Atezolizumab, Lurbinectedin, Carboplatin and Etoposide. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.<\/li>\n<li><strong><em>December 2023: Shanghai Henlius Biotech<\/em><\/strong> announced a study of Phase 3 clinical trials for Serplulimab + chemotherapy (carboplatin-etoposide) and Atezolizumab + chemotherapy (carboplatin-etoposide). A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE).<\/li>\n<li><strong><em>December 2023: Amgen<\/em><\/strong> announced a study of Phase 1 clinical trials for Tarlatamab, Carboplatin, Etoposide, Durvalumab and Atezolizumab. This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Extensive Stage Small Cell Lung Cancer Treatment Drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Extensive Stage Small Cell Lung Cancer Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Extensive Stage Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Extensive Stage Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Extensive Stage Small Cell Lung Cancer clinical trial landscape.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Extensive Stage Small Cell Lung Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Extensive Stage Small Cell Lung Cancer (ESCLC) (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about Extensive Stage Small Cell Lung Cancer Treatment Landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for Extensive Stage Small Cell Lung Cancer Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Extensive Stage Small Cell Lung Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>LY 2510924: Eli Lilly and Company<\/li>\n<li>Tiragolumab: Genentech<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 40+ key Extensive Stage Small Cell Lung Cancer companies which are developing the Extensive Stage Small Cell Lung Cancer therapies. The Extensive Stage Small Cell Lung Cancer companies which have their Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage, i.e. phase III include, Genentech.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Extensive Stage Small Cell Lung Cancer Pipeline Report covers around&nbsp;40+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravitreal<\/li>\n<li>Subretinal<\/li>\n<li>Topical.<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the emerging Extensive Stage Small Cell Lung Cancer Pipeline Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Extensive Stage Small Cell Lung Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Companies- <em>Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., aizhou HoudeAoke Biomedical Co., Ltd., Celgene, MedImmune, Xcovery Holding Company LLC, Lee&#8217;s Pharmaceutical Limited, Merck &amp; Co, Astex Pharmaceuticals,<\/em> and others.<\/li>\n<li>Extensive Stages Small Cell Lung Cancer Pipeline Therapies- <em>Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin\/etoposide<\/em>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for new drugs for Extensive Stage Small Cell Lung Cancer Treatment, Visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Extensive Stage Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Executive Summary<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Overview<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Therapeutic Assessment<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Tiragolumab: Genentech<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>LY 2510924: Eli Lilly and Company<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>SYHA 1807: CSPC ZhongQi Pharmaceutical Technology<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Companies<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Key Products<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Unmet Needs<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Market Drivers and Barriers<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Future Perspectives and Conclusion<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Analyst Views<\/li>\n<li>Extensive Stage Small Cell Lung Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information on the Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics, reach out to <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Extensive Stage Small Cell Lung Cancer Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=extensive-stage-small-cell-lung-cancer-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=extensive-stage-small-cell-lung-cancer-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Extensive Stage Small Cell Lung Cancer Pipeline Insight 2023&rdquo; report provides comprehensive insights about 40+ Extensive Stage Small Cell Lung Cancer companies and 40+ pipeline drugs in the Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/extensive-stage-small-cell-lung-cancer-pipeline-fda-approvals-clinical-trials-developments-and-companies-2023-updated_682203.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-682203","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/682203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=682203"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/682203\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=682203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=682203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=682203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}